Technical Dashboard: Alembic Pharma
Alembic Pharma’s six-week setup depends on holding above its moving-average region and building on the recent increase in volume. The September 24 close of Rs. 850 is about 3.8% above the 50 DMA and 4.6% above the 200 DMA. That provides a useful reference for monitoring the trend, although a moving average does not guarantee support.
| Scenario | Level to Watch | Chanakya Action |
|---|---|---|
| Orderly pullback | Rs. 835–850 | Consider entry only if the price stabilises |
| Breakout | Sustained trade above Rs. 865 | Consider entry if volume remains healthy |
| First objective | Rs. 920 | Review momentum and book partial profits |
| Extended objective | Rs. 960 | Trail the remaining position |
| Setup weakens | Below Rs. 810 | Exit the dip trade and reassess |
Risk–Reward by Entry
An entry near Rs. 850 with a Rs. 810 stop risks about Rs. 40 per share. The proposed gains to Rs. 920 and Rs. 960 are about Rs. 70 and Rs. 110 respectively. This gives approximate reward-to-risk ratios of 1.75:1 and 2.75:1, before costs and slippage.
A breakout entry just above Rs. 865 with a Rs. 830 stop risks around Rs. 35. Its first objective offers roughly Rs. 55 of upside. The actual ratio will change with the execution price; avoid a large gap-up that materially reduces it.
What Confirms the Move?
For the dip approach, look for the stock to stop declining within the proposed entry zone and then regain upward momentum. For the breakout approach, watch whether it holds above Rs. 865, rather than crossing the level briefly. Volume near or above the supplied one-month average of 2.15 lakh shares would provide useful confirmation.
MACD remaining above its signal line would support the bullish view. An RSI move higher accompanied by a stalled price, however, would call for greater caution. The supplied snapshot does not include ADX, DMI or shorter EMAs, so their confirmation should be checked separately.
Business Factor to Monitor
Pharmaceutical results can influence a technical trade abruptly. Alembic’s FY26 investor presentation reported higher R&D spending, partly linked to peptide development and filings. That is relevant when assessing future margins, though it does not establish a six-week price target.
Chanakya Final View
The preferred plan is a controlled entry, followed by disciplined profit-booking. Keep the initial stop tied to the chosen entry method. If Rs. 920 is reached, consider selling part of the holding and moving the stop on the balance towards the actual purchase price. If the price falls below the relevant stop before momentum develops, exit rather than extend the six-week holding period automatically.